The phase II single‐arm PICCOLO trial (NCT05041257) is evaluating MIRV as a monotherapy for patients with FRα‐positive platinum‐sensitive ovarian cancer who have received 1–3 prior therapies. Here, FOLR1 is linked to ovarian carcinoma.